## **Symbiox Investment & Trading Co Ltd**

Date: 1<sup>st</sup> August, 2022

| Vibevor Towers 4th floor plat Nr. 0.00 | 7, Lyons Range, | To,<br><b>The Bombay Stock</b><br><b>Exchange Limited,</b><br>PJ Towers, Dalal Street<br>Mumbai- 400 001 |  |
|--|-----------------|--|--|
|  |                 | ļ  |  |

# Sub: Unaudited Financial result for the guarter ended 30.06.2022

BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

#### Dear Sir,

This is to inform you that Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirement) Regulation 2015, the Board of Directors of the company at their meeting held on 1<sup>st</sup> August, 2022, have approved the Unaudited Financial Results of the company for the quarter ended 30<sup>th</sup> June, 2022.

- Approved the Unaudited Financial Results (Standalone) for the Quarter ended on 30<sup>th</sup> June, 2022 as recommended by the Audit committee.
- 2. Auditor's Limited Review Report in the prescribed format issued by the Statutory Auditor of the Company also attached herewith
- 3. No other matter was discussed at the meeting of the board.

Please take the same on your record and acknowledge the receipt of the same.

Thanking You. Yours Faithfully,

## For Symbiox Investment & Trading Co Ltd

Neha tonson' Neha Pansari

Company Secretary M. No. 31763





Independent Auditors' Limited Review Report on quarterly unaudited standalone financial results of Symbiox Investment & Trading Co Ltd pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors, **Symbiox Investment & Trading Co Ltd** ZA, Rani Rashmoni Road Kolkata- 700 013

1. We have reviewed the accompanying statement of unaudited financial results of Symbiox Investment & Trading Co Ltd ('the Company') for the quarter June 30, 2022 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements') Regulations, 2015.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our 3. that causes us to believe that the accompanying Statement of unaudited attention financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. including the manner in which it is to be disclosed, or that it contains any material misstatement

For Manabendra Bhattacharyya & Co. **Chartered Accountants** ICAI Firm Registration: 302030E

Amit Bhattacharjee Proprietor Membership Number: 050714 UDIN: 22050714ANZOUQ4485

Accountants

tolkata

Place of Signature: Kolkata Date: 01/08/2022

### SYMBIOX INVESTMENT & TRADING CO LTD 7A, RANI RASHMONI ROAD KOLKATA - 700013. CIN - L65993WB1979PLC032012

### Email - symbioxinvestment100@gmail.com; Website: www. symbioxinvestment.com

|   | (Rupees in Lakh except EPS)                  |               |            |                                       |                                       |  |  |
|---|--|---------------|------------|---------------------------------------|---------------------------------------|--|--|
|   | Particulars                                  | Quarter ended |            |                                       | Year ended                            |  |  |
|   |  | 30-06-2022    | 31-03-2022 | 30-06-2021                            | 31-03-2022                            |  |  |
|   | B  | Unaudited     | Audited    | Unaudited                             | Audited                               |  |  |
|   | Revenue From Operations                      | 252.00        |            | 0.00                                  | 105.28                                |  |  |
|   | Other Income                                 | 21.88         |            | 13.86                                 | 71.81                                 |  |  |
|   | Total Income (I+II)                          | 273.88        | 34.11      | 13.86                                 | 177.09                                |  |  |
| 1                                       | Cost of materials consumed                   |               |            | ······                                |                                       |  |  |
|   | Purchases of Stock-in-Trade                  | -             | -          |                                       |                                       |  |  |
|   |  | 191.25        | 51.41      | 0.00                                  | 109.47                                |  |  |
|   | Changes in inventories of finished goods,    |               |            |                                       |                                       |  |  |
|   | Stock-in -Trade and work-in-progress         | 0.00          | 0.00       | 0.00                                  | 0.00                                  |  |  |
|   | Employee benefits expense                    | 5.12          | 7.75       | 3.50                                  | 16.30                                 |  |  |
|   | Finance costs                                | -             | -          | -                                     | -                                     |  |  |
|   | Depreciation and amortization expense        | 0.00          | 0.00       | 0.00                                  | 0.00                                  |  |  |
| ··                                      | Other expenses                               | 7.87          | 5.77       | 8.57                                  | 32.55                                 |  |  |
|   | Total expenses (IV)                          | 204.24        | 64.93      | 12.07                                 | 158.32                                |  |  |
|   | Profit/(loss) before exceptional items and   |               |            |                                       |                                       |  |  |
| V                                       | tax (I- IV)                                  | 69.64         | -30.82     | 1.79                                  | 18.77                                 |  |  |
| VI                                      | Exceptional Items                            | -             | -          | -                                     |                                       |  |  |
|   | Profit/(loss) before tax                     |               |            |                                       | · · · · · · · · · · · · · · · · · · · |  |  |
| VII                                     | (V-VI)                                       | 69.64         | -30.82     | 1.79                                  | 18.77                                 |  |  |
| VIII                                    | Tax expense:                                 |               |            |                                       |                                       |  |  |
|   | (1) Current tax                              | 18.11         | -7.57      | 0.46                                  | 4.88                                  |  |  |
|   | (2) Deferred tax                             |               |            | -                                     |                                       |  |  |
|   | Profit (Loss) for the period from            |               |            | · · · · · · · · · · · · · · · · · · · |                                       |  |  |
| IX                                      | continuing operations (VII-VIII)             | 51.53         | -23.25     | 1.33                                  | 13.89                                 |  |  |
| Х                                       | Profit/(loss) from discontinued operations   | -             |            |                                       |                                       |  |  |
| XI                                      | Tax expense of discontinued operations       | -             | *          | · · · · · · ·                         |                                       |  |  |
| • | Profit/(loss) from Discontinued operations   |               |            |                                       |                                       |  |  |
| XII                                     | (after tax) (X-XI)                           | 51.53         | -23.25     | 1.33                                  | 13.89                                 |  |  |
| XIII                                    | Profit/(loss) for the period (IX+XII)        | 51.53         | -23.25     | 1.33                                  | 13.89                                 |  |  |
| XIV                                     | Other Comprehensive Income                   |               |            |                                       |                                       |  |  |
|   | A (i) Items that will not be reclassified to |               |            |                                       |                                       |  |  |
|   | profit or loss                               | _             | _          | _                                     |                                       |  |  |
|   | (ii) Income tax relating to items that will  |               |            |                                       |                                       |  |  |
|   | not be reclassified to profit or loss        | _             | _          | _                                     |                                       |  |  |

Satement of Unaudited Financial Result for the Quarter ended 30th June, 2022



|       | B (i) Items that will be reclassified to   |       |        |       | ····· |  |  |  |
|-------|--|-------|--------|-------|-------|--|--|--|
|       | profit or loss   | _     | _      | -     |       |  |  |  |
|       | (ii) Income tax relating to items that will  |       |        |       |       |  |  |  |
|       | be reclassified to profit or loss  | -     | -      | _     |       |  |  |  |
|       | Total Comprehensive Income for the   |       |        |       |       |  |  |  |
|       | period (XIII+XIV)(Comprising Profit  |       |        |       |       |  |  |  |
|       | (Loss) and Other Comprehensive Income  |       |        |       |       |  |  |  |
| XV    | for the period)  | -     | -      | -     |       |  |  |  |
|       | Earnings per equity share (for continuing  |       |        |       |       |  |  |  |
| XVI   | operation):  |       |        |       |       |  |  |  |
|       | (1) Basic  | 0.165 | 0.074  | 0.004 | 0.044 |  |  |  |
|       | (2) Diluted  | 0.165 | -0.074 | 0.004 | 0.044 |  |  |  |
|       | Earnings per equity share (for discontinued  |       |        |       |       |  |  |  |
| XVII  | operation):  |       |        |       |       |  |  |  |
|       | (1) Basic  | 0.000 | 0.000  | 0.000 | 0.000 |  |  |  |
|       | (2) Diluted  | 0.000 | 0.000  | 0.000 | 0.000 |  |  |  |
|       | Earnings per equity share(for discontinued   |       |        |       |       |  |  |  |
| KVIII | & continuing operations)   |       |        |       |       |  |  |  |
|       | (1) Basic  | 0.000 | 0.000  | 0.000 | 0.000 |  |  |  |
|       | (2) Diluted  | 0.000 | 0.000  | 0.000 | 0.000 |  |  |  |
| lote: |  | ····· | I      |       |       |  |  |  |
|       |  |       |        |       |       |  |  |  |
| 1     | The above unaudited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 1st August, 2022  |       |        |       |       |  |  |  |
| 2     | The previous period figures have been regrouped wherever necessary.  |       |        |       |       |  |  |  |
| 3     | The Statutory auditors of the Company have carried out a "Auditor's report" of the above results as per  |       |        |       |       |  |  |  |
| 4     | Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.<br>The Company has adopted Indian Accounting standards (Ind AS) with effect from 01 <sup>st</sup> April, 2017 and<br>accordingly, the above results have been prepared in accordance with the Companies (Indian Accounting<br>Standard) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 |       |        |       |       |  |  |  |

5 The above results for the quarter ended 30th June,2022 along with Auditor Report has been approved by the Board of Directors of the Company.

#### For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD

Place: Kolkata Date: 01.08.2022

NT Mina Devi Agarwal KOLKATA Director DIN No. 07370734